共 9 条
[3]
中国卫生统计年鉴[M]. 中国协和医科大学出版社 , 中华人民共和国卫生部编, 2003
[4]
Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial[J] . Mark J. Sculpher,Greta Lozano-Ortega,Jennifer Sambrook,Stephen Palmer,Orges Ormanidhi,Ameet Bakhai,Marcus Flather,P. Gabriel Steg,Shamir R. Mehta,William Weintraub.American Heart Journal . 2009 (5)
[5]
Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions[J] . ElisabethFenwick,Bernie J.O’Brien,AndrewBriggs.Health Econ. . 2004 (5)
[7]
Global cardiovascular disease prevention: time to get serious[J] . Robert Beaglehole.The Lancet . 2001 (9282)
[9]
Decision modelling for health economic evaluation. A. Briggs,M. Schulper,K. Claxton. . 2006